Treatment response according to treatment arm for randomized patients and transplant recipients only
| . | Randomized patients . | Transplant recipients . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | Auto-SCT n = 54 . | Allo-SCT n = 49 . | Auto-SCT* n = 41 . | Allo-SCT n = 26 . | ||||
| . | n/group (%) . | 95% CI . | n/group (%) . | 95% CI . | n/group (%) . | 95% CI . | n/group (%) . | 95% CI . |
| Treatment response | ||||||||
| CR/CRu | 21/54 (39) | 26-53 | 25/49 (51) | 36-66 | 26/41 (63) | 47-78 | 19/26 (73) | 52-88 |
| CR/CRu/untreated PR | 30/54 (56) | 41-69 | 28/49 (57) | 42-71 | 36/41 (88) | 74-96 | 21/26 (81) | 61-93 |
| Relapse after CR/CRu | 7/21 (33) | 15-57 | 3/25 (12) | 3-31 | 10/26 (38) | 20-59 | 0/19 (0) | 0-18 |
| Relapse after CR/CRu/untreated PR | 9/30 (30) | 15-49 | 4/28 (14) | 4-33 | 13/36 (36) | 21-54 | 0/21 (0) | 0-16 |
| EFS events | ||||||||
| PD at the end of therapy | 19/54 (35) | 16/49 (33) | 5/41 (12) | 1/26 (4) | ||||
| Relapse after CR, CRu | 7/54 (13) | 3/49 (6) | 10/41 (24) | 0/26 (0) | ||||
| Relapse after untreated PR | 2/54 (4) | 1/49 (2) | 3/41 (7) | 0/26 (0) | ||||
| Treated PR | 0/54 (0) | 1/49 (2)† | 0/41 (0) | 0/26 (0) | ||||
| SD | 2/54 (4)‡ | 0/49 (0) | 0/41 (0) | 0/26 (0) | ||||
| Unknown | 3/54 (6)† | 0/49 (0) | 0/41 (0) | 0/26 (0) | ||||
| Death after CR, CRu, untreated PR | 1/54 (2) | 8/49 (16) | 1/41 (2) | 8/26 (31) | ||||
| EFS, PFS, OS rates with 95 CI | ||||||||
| 3-y EFS | 38 | 25-52 | 43 | 29-57 | 57 | 42-73 | 65 | 47-84 |
| 3-y PFS | 39 | 26-52 | 43 | 29-57 | 57 | 42-73 | 65 | 47-84 |
| 3-y OS | 70 | 57-82 | 57 | 43-71 | 81 | 68-93 | 65 | 47-84 |
| . | Randomized patients . | Transplant recipients . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | Auto-SCT n = 54 . | Allo-SCT n = 49 . | Auto-SCT* n = 41 . | Allo-SCT n = 26 . | ||||
| . | n/group (%) . | 95% CI . | n/group (%) . | 95% CI . | n/group (%) . | 95% CI . | n/group (%) . | 95% CI . |
| Treatment response | ||||||||
| CR/CRu | 21/54 (39) | 26-53 | 25/49 (51) | 36-66 | 26/41 (63) | 47-78 | 19/26 (73) | 52-88 |
| CR/CRu/untreated PR | 30/54 (56) | 41-69 | 28/49 (57) | 42-71 | 36/41 (88) | 74-96 | 21/26 (81) | 61-93 |
| Relapse after CR/CRu | 7/21 (33) | 15-57 | 3/25 (12) | 3-31 | 10/26 (38) | 20-59 | 0/19 (0) | 0-18 |
| Relapse after CR/CRu/untreated PR | 9/30 (30) | 15-49 | 4/28 (14) | 4-33 | 13/36 (36) | 21-54 | 0/21 (0) | 0-16 |
| EFS events | ||||||||
| PD at the end of therapy | 19/54 (35) | 16/49 (33) | 5/41 (12) | 1/26 (4) | ||||
| Relapse after CR, CRu | 7/54 (13) | 3/49 (6) | 10/41 (24) | 0/26 (0) | ||||
| Relapse after untreated PR | 2/54 (4) | 1/49 (2) | 3/41 (7) | 0/26 (0) | ||||
| Treated PR | 0/54 (0) | 1/49 (2)† | 0/41 (0) | 0/26 (0) | ||||
| SD | 2/54 (4)‡ | 0/49 (0) | 0/41 (0) | 0/26 (0) | ||||
| Unknown | 3/54 (6)† | 0/49 (0) | 0/41 (0) | 0/26 (0) | ||||
| Death after CR, CRu, untreated PR | 1/54 (2) | 8/49 (16) | 1/41 (2) | 8/26 (31) | ||||
| EFS, PFS, OS rates with 95 CI | ||||||||
| 3-y EFS | 38 | 25-52 | 43 | 29-57 | 57 | 42-73 | 65 | 47-84 |
| 3-y PFS | 39 | 26-52 | 43 | 29-57 | 57 | 42-73 | 65 | 47-84 |
| 3-y OS | 70 | 57-82 | 57 | 43-71 | 81 | 68-93 | 65 | 47-84 |